Table 4.

Univariate and multivariate cox regression analyses

Variables	TTP					OS
	Univariate		Multivariate			Univariate		Multivariate
	HR (95% Cl)	P	HR (95% Cl)	P		HR (95% Cl)	P	HR (95% Cl)	P
Gender (Male vs. Female)	0.956(0.634–1.441)	0.830			0.821(0.507–1.328)		0.421
Age (< 60 vs. ≥ 60)	0.905(0.595–1.377)	0.642			1.583(0.979–2.559)		0.061
Smoking status (No vs. Yes)	1.333(0.820–2.165)	0.246			1.472(0.846–2.560)		0.171
ECOG PS (0–1 vs. 2)	2.694(0.974–7.455)	0.056			1.429(0.445–4.590)		0.549
Clinical stage (IIIB/C vs. IV)	1.188(0.682–2.069)	0.543			3.135(1.417–6.935)		0.005	2.640(1.061–6.564)	0.037
Brain metastases (No vs. Yes)	1.892(1.200–2.984)	0.006	2.065(1.305–3.269)	0.002	1.950(1.162–3.270)		0.011	2.136(1.207–3.781)	0.009
Bone metastases (No vs. Yes)	1.100(0.731–1.654)	0.648			1.796(1.106–2.918)		0.018	1.517(0.892–2.580)	0.124
Liver metastases (No vs. Yes)	1.256(0.665–2.372)	0.482			2.171(1.096–4.301)		0.026	1.365(0.666–2.798)	0.396
EGFR 21 L858R mutation (No vs. Yes)	0.903(0.734–1.111)	0.333			0.774 (0.610–0.982)		0.035	2.221(1.314–3.752)	0.003
TP53 mutation (Exon8 vs. Other Exons)	0.835(0.490–1.424)	0.509			0.795 (0.431–1.465)		0.462
T790M status at progression (NA vs. Positive)	0.673(0.445–1.018)	0.061			0.378(0.227–0.631)		P < 0.001	0.294(0.169–0.510)	P < 0.001
Treatment (T vs. TC)	0.465(0.297–0.728)	0.001	0.438(0.279–0.687)	P < 0.001	0.623 (0.364–1.065)		0.084

HR hazard ratio, CI confidence interval, NA unknown or unable to perform check calculation